Archive for March, 2004

h1

108070215688192006

March 30, 2004

The 5% Shuffle – How not to get funded
Before you go ahead and pitch your potential to capture some percentage of a market, read this article. Bottom line: market’s aren’t captured, spending budgets are. Focus on capturing your customer’s budgets, not the “market.”

Advertisements
h1

108009981653896015

March 23, 2004

A Drug Behemoth In The Making?
“Novartis plus Aventis would create the world’s No. 2 drugmaker, unless politics get in the way “

h1

107998342913944824

March 22, 2004

Is genetic engineering next doping threat?
Experts worry that biotechnology could infiltrate sports

h1

107971299216859805

March 19, 2004

Boy May Force Change in Norway Bio-Ethics Law
“A campaign to save a six-year-old Norwegian boy with a life-threatening blood disorder looked likely Thursday to force Norway to relax strict biotechnology laws in a stinging defeat for the government. “

h1

107965107078712702

March 18, 2004

Drug Prices: The Genentech Solution
“If developed nations want access to breakthrough medicines, they should have to pay full price, says Genentech Chief Executive Arthur D. Levinson. “

h1

107962957899854167

March 18, 2004

Amgen Opens The Secret Curtain
“The biotech leader will host analysts and investors to drum up excitement for its pipeline — and its stock. Will it work? “

h1

107876301300090959

March 8, 2004

Biotech uptick moves into March:
“February went out like a lion in biotechnology as filings for initial public offerings (IPOs) by three companies capped a flurry of activity in the sector. Acadia Pharmaceuticals, Alnylam Pharmaceuticals, and Ark Therapeutics announced filings in the wake of strong openings on Wall Street last month for GTx, Renovis, Corgentech, and DynaVax Technologies.”